TITLE

GENMAB/ROCHE ANNOUNCE ANTIBODY DEVELOPMENT COLLABORATION

PUB. DATE
June 2001
SOURCE
Worldwide Biotech;Jun2001, Vol. 13 Issue 6, p7
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Announces the broad collaboration of Genmab A/S with the Roche company for the creation and development of human antibody therapeutics.
ACCESSION #
4570810

 

Related Articles

  • Genmab and Sanquin collaborate on hemophilia research.  // PharmaWatch: Biotechnology;February 2004, Vol. 3 Issue 2, p11 

    Reports that Genmab AS has entered into a research venture with the Sanquin Blood Supply Foundation to develop and improve hemophiliac treatment. Discovery of a method for preventing inhibitory antibodies from binding to factor VIII therapy; Utilization of antibodies to block the sites where the...

  • Genmab Further Validates its DuoBodyâ„¢ Technology with Janssen Biotech Agreement. Cartwright, Heather // PharmaDeals Review;2012, Vol. 2012 Issue 7, p103 

    Genmab has made further progress with its DuoBodyâ„¢ technology platform by agreeing to collaborate with Johnson & Johnson's Janssen Biotech to create and develop bispecific antibodies against multiple disease targets. Janssen will fund all research and Genmab will receive US$3.5 M upfront...

  • GENMAB/IMMUNEX TO DISCOVER AND DEVELOP CANCER ANTIBODY.  // Worldwide Biotech;Nov2001, Vol. 13 Issue 11, p6 

    Presents information on a collaborative agreement of Genmab A/S with Immunex Corporation to discover and develop an antibody against lymphoma as of November 2001.

  • EARNINGS ROUNDUP.  // BioWorld Today;2/6/2014, Vol. 25 Issue 25, p3 

    The article reports on the 30.5-million-dollar net sales achieved by Gen mab A/S's anti-CD20 antibody Arzerra (ofatumumab) in the fourth quarter of 2013.

  • GSK and Genmab submit ofatumumab application to FDA.  // Hem/Onc Today;3/10/2009, Vol. 10 Issue 5, p49 

    The article reports on the submission of a Biologics License Application to the U.S. Food and Drug Administratino (FDA) by GlaxoSmithKline and Genmab.

  • Clinic Roundup.  // BioWorld Today;3/20/2012, Vol. 23 Issue 44, p8 

    The article reports that Genmab A/S submitted a protocol amendment for its ofatumumab Phase III head-to-head study in diffuse large B-cell lymphoma (DLBCL).

  • Serono is investing in Genmab antibody.  // Chemical Market Reporter;8/22/2005, Vol. 268 Issue 6, p7 

    Reports on European biotechnology company Serono's plan to invest in Genmab AS as part of an agreement in which Serono gets exclusive worldwide rights to develop and commercialize Genmab's oncology monoclonal antibody, HuMax-CD4 (zanolimumab). Terms of the agreement; Development of the HuMax-CD4...

  • Arzerra net sales in Q2 2012 were GBP 14.9 million.  // Biotech Financial Reports;Aug2012, Vol. 19 Issue 8, p6 

    The article reports on the net sales of Copenhagen, Denmark-based biotechnology company Genmab A/S's Arzerra (ofatumumab) in the second quarter of 2012. It states that net sales of Arzerra reached 14.9 million pounds which consists of net sales in the U.S. of 9.4 million pounds and 5.5 million...

  • Genmab, Lundbeck Collaborate on Antibodies.  // Drug Discovery & Development;Nov2010, Vol. 13 Issue 9, p23 

    The article reports on the announcement of Genmab A/S regarding an agreement with H. Lundbeck A/S. that it will create and develop human antibody therapeutics for disorders of the central nervous system.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics